Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Anatara Lifesciences Ltd ( (AU:ANR) ).
Anatara Lifesciences Ltd has announced the completion of Stage 2 of its Phase II GaRP-IBS trial, revealing that while the primary efficacy endpoint was not met, significant findings were observed. The trial showed no safety concerns, and secondary endpoints indicated improvements in anxiety scores and IBS-Adequate Relief, suggesting potential benefits to the gut-brain axis. The company plans to leverage these findings for commercial opportunities and is also progressing with its anti-obesity project.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focused on addressing significant unmet needs in human health, particularly conditions involving the complexity of the gastrointestinal tract.
YTD Price Performance: -78.00%
Average Trading Volume: 1,197,997
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.28M
See more data about ANR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue